ClinicalTrials.gg
Not yet recruitingNCT07944690Updated Nov 18, 2026

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors

A Phase 1 interventional study of HLX49 and Trastuzumab Deruxtecan for Injection (T-DXd) in Advanced/Metastatic Solid Tumors, sponsored by Shanghai Henlius Biotech. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of HLX49 in patients with advanced/metastatic solid tumors.

Read the detailed description

In the phase Ia of this study, an accelerated titration and 3 + 3 dose escalation method will be adopted, and the patients will be administered with HLX49 at different doses via intravenous infusion. The DLT observation period lasts for 3 weeks after the first administration of HLX49.

In phase Ib of this study, the Safety Review Committee will recommend dose groups for expansion based on the safety, efficacy, and PK data of the dose escalation phase. The dose expansion part will enroll patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have previously failed first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. Patients will be randomized to receive different doses of HLX49 or the active comparator (trastuzumab deruxtecan, T-DXd).

02

Conditions studied

  • Advanced/Metastatic Solid Tumors
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 133 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written and comply with the study protocol.
  2. Age: 18 to 75 years for Phase Ia; ≥ 18 years for Phase Ib. 3.Tumor Type \& Prior Treatment: Phase Ia: or cytologically confirmed advanced or solid tumors that are to standard treatment, or for which no standard treatment is available.

Phase Ib (GC/GEJC cohort): Histologically or cytologically confirmed advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) that has progressed during or after exactly one containing trastuzumab (or a biosimilar).

4.Confirmed -positive status (Phase Ia: IHC 3+ or 2+; Phase Ib: IHC 3+ or IHC 2+/ISH+).

5. performance status score of 0 or 1. 6.At least one . 7. of more than 3 months. 8.Adequate from prior treatments (e.g., at least 28 days for chemotherapy, radiotherapy, immunotherapy, or major surgery; at least 14 days for targeted therapy or hormone therapy) and recovery of previous treatment-related adverse events.

9.Must provide a tumor tissue sample for biomarker evaluation. 10.Adequate organ and bone marrow function as defined by protocol-specified laboratory tests.

11.Male and female participants with must agree to use highly effective methods; female participants of must have a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  1. History of other malignant tumors within 2 years prior to the first dose (with exceptions for cured early-stage cancers like cervical carcinoma in situ or non-melanoma skin cancer).
  2. History of severe eye diseases (e.g., severe keratopathy or moderate to severe dry eye).
  3. History of or current interstitial lung disease (ILD) or non-infectious pneumonitis requiring systemic .
  4. Severe allergic reactions to monoclonal antibodies or allergy to any component of the product.
  5. Active systemic infections requiring intravenous antibiotics.
  6. Requirement for treatment with systemic corticosteroids or other medications within 2 weeks prior to the first dose.
  7. cardiovascular diseases, including but not limited to: severe/unstable angina, myocardial infarction within 6 months, symptomatic congestive heart failure, \<50%, poorly controlled hypertension, or clinically significant prolonged .
  8. Symptomatic or uncontrolled brain or meningeal , or spinal cord compression.
  9. Active or suspected diseases (exceptions apply for well-controlled type 1 diabetes and autoimmune hypothyroidism on replacement therapy).
  10. Unhealed major wounds or anticipation of major surgery during the study.
  11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
  12. Use of strong inhibitors or inducers within 2 weeks prior to the first dose.
  13. Active tuberculosis.
  14. Known history of immunodeficiency, including , or history of solid organ transplantation.
  15. Active (HBV) or (HCV) infection (exceptions apply for stable/controlled HBV or HCV meeting specific viral load criteria).
  16. Pregnant or breastfeeding females.
  17. Subjects who are assessed as unsuitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons by the investigator.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
222 participants (estimated)

Study arms

  • Experimental
    Ia (Dose Escalation)

    Patients with advanced/metastatic solid tumors, who are refractory to standard treatment or for which no standard treatment is available.

    Drug: HLX49

  • Experimental
    Ib HLX49 Dose 1 (Dose Expansion)

    Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

    Drug: HLX49

  • Experimental
    Ib HLX49 Dose 2 (Dose Expansion)

    Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

    Drug: HLX49

  • Experimental
    Ib HLX49 Dose 3 (Dose Expansion)

    Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

    Drug: HLX49

  • Active comparator
    Ib Trastuzumab deruxtecan (Dose Expansion)

    Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

    Drug: Trastuzumab Deruxtecan for Injection (T-DXd)

Interventions

  • DrugHLX49

    Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

  • Patients with good tolerability and well controlled disease will receive Trastuzumab deruxtecan via intravenous infusion once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

06

What researchers measure

Primary outcomes

  1. The Dose-Limiting Toxicity (DLT) of HLX49 within 21 days after the first Administration

    DLT refers to the AEs that are determined to be related to the investigational product by the investigator, whose severity will affect the escalation of dose level. In this study, the DLT observation period lasts for 3 weeks (21 days) after the first administration of HLX49.

    Time frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks).

  2. The maximum tolerated dose (MTD) of HLX49

    The highest dose level, at which DLT is observed in no more than one of 6 evaluable patients, is defined as MTD of HLX49.

    Time frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks).

  3. RP2D

    The recommended phase 2 dose (RP2D) of HLX49 in participants with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma.

    Time frame: Approximately up to 24 months.

  4. Objective response rate (ORR) assessed by IRRC

    Percentage of participants with complete response (CR) and partial response (PR) based on independent radiographic review committee (IRRC) assessment.

    Time frame: Approximately up to 24 months.

Secondary outcomes

  1. Objective response rate (ORR)

    Percentage of participants with complete response (CR) and partial response (PR) based on investigator assessment.

    Time frame: Approximately up to 24 months.

  2. Duration of response (DOR)

    Length of time response continued based on investigator and IRRC assessment.

    Time frame: Approximately up to 24 months.

  3. Progression-free survival (PFS)

    The PFS is defined as the time from the date of enrollment to the date of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause, whichever occurred first.

    Time frame: Approximately up to 24 months.

  4. Overall survival (OS)

    Time from the date of enrollment to the date of death for any cause.

    Time frame: Approximately up to 24 months.

  5. Cmax

    Maximum serum concentration (Cmax) of HLX49, total antibody, and free payload.

    Time frame: Up to 21 days after the first dose.

  6. Tmax

    Time to maximum serum concentration (Tmax) of HLX49, total antibody, and free payload.

    Time frame: Up to 21 days after the first dose.

  7. T1/2

    Elimination half-life (t1/2) of HLX49, total antibody, and free payload.

    Time frame: Up to 21 days after the first dose.

  8. ADA (anti-drug antibody)

    Positive rate of anti-HLX49 antibodies (ADA).

    Time frame: Approximately up to 24 months.

  9. NAb (neutralizing antibody)

    Positive rate of neutralizing antibodies (NAb) against HLX49.

    Time frame: Approximately up to 24 months.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2029, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944690
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Lin Shen
Contact
doctorshenlin@sina.cn
+86 10 88196561

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion